The landscape of drug development is poised for a significant transformation, thanks to a groundbreaking initiative led by researchers at the La Jolla-based Sanford Burnham Prebys Medical Discovery Institute. This ambitious project, known as PREDICTS, aims to bridge the gap between scientific aspiration and successful outcomes in drug delivery.
Funding and Goals
Recently, the U.S. Department of Health and Human Services, through its Advanced Research Projects Agency for Health (ARPA-H), allocated $31.7 million to this multi-institutional endeavor. The primary objective of PREDICTS, which stands for Pharmacological Research and Evaluation through Digital Integration and Clinical Trial Simulation, is to harness advanced computational models to predict human toxicity.
Dr. David Brenner, president and CEO of Sanford Burnham Prebys, emphasizes the transformative potential of this initiative. By streamlining the drug development timeline, the project aims to reduce the typical 10-15 year process and the associated costs, which can exceed $2 billion. Currently, an alarming 90% of drug development efforts fail, underscoring the urgent need for innovation in this field.
Reducing Reliance on Animal Testing
The PREDICTS initiative aligns with a notable shift within the U.S. Food and Drug Administration (FDA). The agency is moving away from stringent animal testing protocols and is increasingly adopting new approach methodologies (NAMs). These methodologies include innovative alternatives such as organoids and artificial intelligence-driven computational modeling.
Steven Olson, the executive director of medicinal chemistry at the institute’s Center for Therapeutics Discovery, acknowledges the limitations of traditional animal models. What appears safe in these models can be ineffective or even toxic in humans. Thus, the PREDICTS project seeks to provide robust scientific evidence that supports the efficacy of computational approaches over traditional methods.
A New Paradigm in Drug Discovery
The PREDICTS platform is part of a broader ARPA-H program known as CATALYST, which stands for Computational ADME-Tox and Physiology Analysis for Safer Therapeutics. This initiative aims to develop advanced computer models that accurately reflect human physiology, enabling researchers to evaluate investigational drug candidates more effectively.
Sanford Burnham Prebys is collaborating with a consortium of research institutions to create the first “virtual human safety platform.” This innovative platform will predict how small molecules and drug candidates interact within the human body, potentially revolutionizing the drug discovery process.
Components of the PREDICTS Platform
The PREDICTS initiative comprises three essential components. First, it will establish a cloud-based repository designed to develop comprehensive datasets. Second, the project will focus on training machine learning models to identify safety liabilities associated with drug candidates. Finally, it will evaluate the performance of these machine learning models against traditional testing methods.
Olson notes the excitement surrounding this scientific endeavor. If successful, the PREDICTS initiative could fundamentally alter the landscape of drug discovery, expediting the process of bringing new therapies to patients while enhancing accuracy and safety.
Implications for Future Research
The implications of the PREDICTS project extend beyond improving drug delivery timelines. By reducing the reliance on animal testing and adopting innovative computational approaches, this initiative could lead to more ethical research practices in the pharmaceutical industry. Furthermore, it may contribute to significant advancements in personalized medicine by providing insights tailored to individual patient responses.
Conclusion
The PREDICTS initiative represents a bold step forward in the quest to revolutionize drug development. By leveraging cutting-edge technology and innovative methodologies, researchers at the La Jolla Institute aim to accelerate the delivery of safe and effective therapies. This initiative not only promises to enhance the efficiency of drug discovery but also paves the way for a more humane approach to medical research.
- PREDICTS aims to transform drug development timelines.
- The initiative focuses on reducing reliance on animal testing.
- Collaboration among research institutions enhances the project’s scope.
- Machine learning models will identify safety liabilities in drug candidates.
- The project supports ethical research practices in the pharmaceutical industry.
Source: www.sandiegouniontribune.com